ALX Oncology Announces First Patients Dosed With Evorpacept And Sarclisa As Part Of Randomized Phase 1/2 UMBRELLA Study With Sanofi
ALX Oncology Announces First Patients Dosed With Evorpacept And Sarclisa As Part Of Randomized Phase 1/2 UMBRELLA Study With Sanofi
ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced the first patients have been dosed in an arm of the randomized UMBRELLA phase 1/2 clinical study partnered with Sanofi that is evaluating evorpacept in combination with SARCLISA (isatuximab-irfc). Evorpacept is ALX Oncology's investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated Fc domain and SARCLISA is Sanofi's approved CD38 monoclonal antibody in patients with relapsed or refractory multiple myeloma (RRMM).
alx oncology控股有限公司（"ALX Oncology"或"該公司") (納斯達克:ALXO)，一家免疫腫瘤學公司，正在開發阻斷CD47免疫檢查點通路的療法，並宣佈已向與賽諾菲安萬特合作的UMBRELLA隨機Ⅰ/Ⅱ期臨床研究的一部分的首批患者投藥，該研究正評估evorpacept聯合SARCLISA（異脲佝體單抗-irfc）。Evorpacept是ALX Oncology的研究中的CD47阻斷療法，它獨特地結合了高親和力的CD47結合結構域和無活性的Fc結構域，而SARCLISA是賽諾菲安萬特在複發性或難治性多發性骨髓瘤（RRMM）患者中獲批的CD38單抗。
SARCLISA binds to a specific epitope on the CD38 receptor on multiple myeloma (MM) cells, inducing distinct antitumor activity. CD38 is highly and uniformly expressed on the surface of MM cells and after first-line treatment, some relapsed or recurred patients have shown resistance to CD38 agents. CD47 expression increases as multiple myeloma progresses, suggesting that evorpacept may have the potential to re-sensitize tumors to CD38 treatment or overcome anti-CD38 resistance. This novel therapeutic combination has demonstrated synergistic anti-tumor activity in preclinical models.
SARCLISA結合多發性骨髓瘤（MM）細胞上CD38受體的特異表位，誘導出獨特的抗腫瘤活性。CD38在Mm細胞表面高度且均勻表達，在一線治療後，部分復發或重發的患者顯示對CD38藥物的抵抗。隨着多發性骨髓瘤的進展，CD47表達增加，表明evorpacept可能具有重新敏感腫瘤對CD38治療或克服抗CD38的潛力。這種新穎的治療組合在臨床前模型中表現出協同的抗腫瘤活性。
譯文內容由第三人軟體翻譯。